OCGN
Ocugen, Inc.
1.12
+
0.00
0.00%
7 x 1.10
7 x 1.13
bid
ask
7 @ 04:00 PM
1.13+0.01 (0.89%)
Bearish
169
Bullish
423
sentiment
1.10
day range
1.18
0.34
52 week range
2.10
News
...
Ocugen Inc. stock falls Tuesday, underperforms market | news.google.com • |
Ocugen Inc. stock falls Tuesday, underperforms market | news.google.com • |
Ocugen Inc. stock falls Tuesday, underperforms market | news.google.com • |
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 | seekingalpha.com • |
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 | news.google.com • |
NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation | news.google.com • |
Profile
...
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | -0.06 | -0.04 | 0.02 | 33.33% |
2024-05-14 | 2024-03 | -0.06 | -0.05 | 0.01 | 16.67% |
2024-04-16 | 2023-12 | 0 | -0.04 | N/A | N/A |
2023-11-09 | 2023-09 | -0.08 | -0.06 | 0.02 | 25.00% |
2023-08-21 | 2023-06 | -0.08 | -0.1 | -0.02 | -25.00% |
2023-05-05 | 2023-03 | -0.11 | -0.07 | 0.04 | 36.36% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-07 | Chardan Capital | Upgrade | Buy | |
2023-04-16 | HC Wainwright & Co. | Upgrade | Buy | |
2023-04-13 | Chardan Capital | Upgrade | Buy | |
2023-02-28 | Chardan Capital | Upgrade | Neutral | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-08-10 | CASTILLO KIRSTEN M | Director | 50.00K | Sale |
2023-01-02 | CRESPO JESSICA | Officer | 163.39K | Stock Award(Grant) |
2021-05-24 | FERNANDES PRABHAVATHI | Director | 0.00 | Sale |
2021-11-01 | KOMPELLA UDAY B. | Director | 0.00 | Sale |
2022-10-05 | KUMAR RAMESH | Director | 0.00 | Sale |
2023-02-15 | MUSUNURI SHANKAR PH.D | Chief Executive Officer | 3.34M | Sale |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 11.81M | 6.41M | 4.60% |
2023-06-29 | Luminus Management, LLC | 4.08M | 2.22M | 1.59% |
2023-06-29 | GMT Capital Corp | 3.92M | 2.13M | 1.53% |
2023-06-29 | Blackrock Inc. | 3.91M | 2.12M | 1.52% |
2023-06-29 | JP Morgan Chase & Company | 3.04M | 1.65M | 1.19% |
2023-06-29 | Millennium Management Llc | 3.02M | 1.64M | 1.18% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 7.60M | 4.13M | 2.96% |
2023-06-29 | Vanguard Extended Market Index Fund | 3.06M | 1.66M | 1.19% |
2023-05-30 | Fidelity Extended Market Index Fund | 1.07M | 490.29K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 921.56K | 423.92K | 0.36% |
2023-05-30 | Vanguard Health Care Index Fund | 738.21K | 339.58K | 0.29% |
2023-05-30 | Vanguard Russell 2000 Index Fund | 597.25K | 274.74K | 0.23% |
Split
...
Split | Date |
---|---|
1 : 60 | 2019-09-30 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
-
-
PATIENTLY LONGS WAITED FOR NEWS. AND, WHEN IT CAME, IT CREATED A DOMINO STOP LOSS DUMP. AT THE SAME TIME, A 15M SHORT SELL WAS ENTERED OVER SEAS. SO, I CALLED THE SEC TO REGISTER A FORMAL COMPLAINT, ONLY TO LEARN FROM THE INVESTIGATOR THAT THE CEO IS ALREADY SUSPECTED OF CRIMINAL ACTIVITY, RELATED TO THE MEGA SHORT SELL, BY FSA. YOU BUY THIS SHIT, YOU COULD LOSE ALL THE MONEY.
-
-
-
-
-
-
-
-
-
-
-
-
-
Ocugen Inc. stock falls Tuesday, underperforms market
news.google.com • -
Ocugen Inc. stock falls Tuesday, underperforms market
news.google.com • -
Ocugen Inc. stock falls Tuesday, underperforms market
news.google.com • -
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
seekingalpha.com • -
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
news.google.com • -
Ocugen Inc. stock rises Friday, outperforms market
news.google.com •